



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/776,780
				Filing Date	February 10, 2004
				First Named Inventor	Matthew During
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	102194-19

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code ² (if known)					
LAL	AA	5,532,265		07-02-1996	Gijbels et al.		
	AB	5,753,624		05-19-1998	McMichael et al.		
	AC	5,827,819		10-27-1998	Yatvin et al.		
	AD	5,851,996		12-22-1998	Kline		
FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
W	BA	2,087,738		07-26-1994	Canada		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind's Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
W	CA	Charles, V et al. "Atrophy of Cholinergic Basal Forebrain Neurons Following Excitotoxic Cortical Lesions is Reversed by Intravenous Administration of an NGF Conjugate", Brain Research, Vol. 728, pps. 193-203 (1996);			
	CB	During, M et al. "Peroral Gene Therapy of Lactose Intolerance Using An Adeno-Associated Virus Vector", Nature Medicine, Vol. 4, No. 10, pps. 1131-1135 (1998);			
	CC	Lobell, A. et al. "Vaccination with DNA Encoding An Immunodominant Myelin Basic Protein Peptide Targeted To Fc Of Immunoglobulin G Suppresses Experimental Autoimmune Encephalomyelitis", Journal of Experimental Medicine, Vol. 187, No. 9, pps. 1543-1548, (1998);			
	CD	Shehr, R. "New Treatments for Acute Stroke", Nature Biotechnology, Vol. 14, pps. 1549-15454 (1996);			
	CE	Schenk, D. et al. "Immunization with Amyloid- β Attenuates Alzheimer-Disease-Like Pathology in the PDAPP Mouse", Nature, Vol. 400, pps. 173-177 (1999);			
	CF	Stanton, P.K. et al. "A Monoclonal Antibody Which Mimicks Glycine Actions On N-Methyl-D-Aspartate Receptors Has Complex Effects On Channel Activation and Neuronal Sensitivity to Hypoxia" Society for Neuroscience Abstracts, Vol. 16, No. 1, pp. 88 (1990)			
	CG	Sun, F. and Faden, A., "Pretreatment With Antisense Oligodeoxynucleotides Directed Against The NMDA-R1 Receptor Enhances Survival and Behavioral Recovery Following Traumatic Brain Injury in Rats" Brain Research, Vol. 693, pps. 163-168 (1995)			
	CH	Wahlestedt, C. et al. "Antisense Oligodeoxynucleotides To NMDA-R1 Receptor Channel Protect Cortical Neurons From Excitotoxicity and Reduce Focal Ischaemic Infarctions", Nature, Vol. 363, pps. 260-263 (1993).			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	11/4/05
-----------------------	--	--------------------	---------

1305990.1